Through integrative analysis combining MR of GM genetics with transcriptomics and scRNA-seq validation, we identified TMOD2 and DOCK4 as novel diagnostic biomarkers for CRA, achieving 88% diagnostic accuracy while revealing their fundamental roles in adenoma pathogenesis through cytoskeletal regulation, cell cycle control, and immune microenvironment modulation. Here, TMOD2 is linked to adenoma.